Matters arising these clinical situations than during HRT. This suggests that ICTP might be a less sensitive marker for changes in bone resorption than expected.
Fibromyalgia in the workplace
Sir: In his leader 'Fibromyalgia in the workplace: a "management" problem" Paul Reilly asks what lessons Britain might learn from the Australian experiences. We suggest that Dr Reilly might have assisted this process had he more adequately considered Australian publications and also the papers describing earlier epidemics in Scandinavia and Japan. He has continued the theme of opinion papers which in Australia led to a distortion of views and discussion in favour of unproved psychological mechanisms and away from scientific research. Presumably because ofthe important implications for economics and industrial relations, and in the absence of adequate knowledge, the unsubstantiated opinions of authorities were given more prominence in Australia than is usual in medical matters. The emphasis on psychosocial causation was effective in reducing the apparent incidence and in influencing the outcome of workers' compensation litigation, but at a cost of considerable distress to many affected workers. It is to be hoped that henceforth editors will insist on clearer distinctions between knowledge and opinions.
The outstanding shortcomings in this paper are inadequacy of the clinical description; the use of invalidated terminology; an uninformed discussion of pain pathophysiology, which ignores essential concepts of hyperalgesia; the omission of any framework for the elucidation of pathogenesis; and the essentially negative approach to the treatment of affected subjects.
Not unreasonably, Dr Reilly suggests that a descriptive diagnosis be applied for example, 'upper is a system of more or less accurate guessing, in which the end point is a name. These names applied to disease come to assume the importance of specific entities, whereas they are for the most part no more than insecure and therefore temporary conceptions'.2 The majority do not now believe that fibromyalgia is due exclusively to pain in fibrous tissue and muscles, any more than Sir William Gowers believed, when he invented the term, that 'fibrositis' was due to inflammation of fibrous tissue. However, the term allows for the investigation of useful concepts in exploring the spectrum of chronic pain syndromes, and a neurogenic basis is not only suggested but also based on hard scientific fact (for reviews see references 3 and 4). According to Champion et al the pain of 'RSI' has its origin in peripheral nociceptive inputs, but these are themselves considerably influenced by neuropeptide down regulation in the spinal cord and by sympathetic efferent activity. Further modification by higher cortical centres is amply illustrated by the influence on pain of anxiety, stress, guided imagery, and the distraction of battles and sporting events.
Having been a research associate of Professor Helme and his team in Melbourne, I am well aware of his work on chronic pain, and have myself presented data on augmented neurogenic inflammation in fibromyalgia.5 This followed up previous work by Helme and colleagues on fibromyalgia and regional pain problems.6 The key term used by Champion et al is 'central sensitisation of nociception', and this occurs reflexly through sympathetic and higher cerebral function. Do we not sweat when anxious, does our hair not stand erect when frightened, and do our muscles not tense at times of danger? These phenomena cannot occur if sensory inputs fail to register in higher centres. In the same way pain is the way in which an individual brain interprets an unpleasant sensation, with this interpretation being dependent on numerous internal and external variables.
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